Selonsertib, an inhibitor of apoptosis signal-regulating kinase 1 (ASK1), targets pathways involved in inflammation and apoptosis, two critical aspects of MASLD pathophysiology. The gene discussed is MAP3K5; the disease is metabolic dysfunction-associated steatotic liver disease.